Does neratinib/neratinib need to be reimbursed by medical insurance?
Neratinib/Neratinib is an oral, irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor of HER1, HER2 and HER4. In the pivotal ExteNET trial of women with early-stage HER2-positive breast cancer who completed adjuvant trastuzumab therapy, 12 months of neratinib treatment significantly reduced the risk of invasive disease recurrence or death compared with placebo at 2 and 5 years after randomization.
Subgroup analysis showed that patients with hormone receptor (HRc)-positive disease benefited more from neratinib than patients with HRc-negative disease, and patients who started treatment with neratinib within 1 year after completing trastuzumab treatment had better prognosis than patients who started treatment 1-2 years after trastuzumab treatment. As with other tyrosine kinase inhibitors, diarrhea that can be prevented and/or controlled with antidiarrheal prevention and/or dose adjustment is the most common adverse event with neratinib.

The original drug Neratinib has entered the scope of national Class B medical insurance reimbursement after being launched in China. Patients who meet the indications can use the national medical insurance for reimbursement, while patients who do not meet the conditions can only purchase the drug at their own expense. Due to different reimbursement ratios in different regions, there may be slight differences in the price after reimbursement. The current domestic price of the original drug Neratinib, specification The price per box of 40mg*180 tablets is approximately RMB 7,000, and the price may be much lower after patients are reimbursed by medical insurance.
There are also overseas pharmaceutical factories currently producing generic drugs of neratinib. The ingredients of the drug are similar to those of the original drug, but the price will be relatively cheap. For example, the specifications produced by Bangladesh Yaopin International The price of 40mg*180 tablets per box may be around 2,000 yuan (the price may fluctuate due to the exchange rate).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)